Repligen Corporation (RGEN)

NASDAQ: RGEN · IEX Real-Time Price · USD
149.96
-0.44 (-0.29%)
May 16, 2022 4:00 PM EDT - Market closed
Market Cap8.34B
Revenue (ttm)734.10M
Net Income (ttm)145.81M
Shares Out55.60M
EPS (ttm)2.53
PE Ratio59.30
Forward PE217.39
Dividendn/a
Ex-Dividend Daten/a
Volume330,172
Open148.99
Previous Close150.40
Day's Range147.20 - 153.39
52-Week Range137.21 - 327.32
Beta0.90
AnalystsBuy
Price Target244.67 (+63.2%)
Earnings DateApr 27, 2022

About RGEN

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput...

IndustryLife Sciences Tools & Services
Founded1981
CEOAnthony Hunt
Employees1,852
Stock ExchangeNASDAQ
Ticker SymbolRGEN
Full Company Profile

Financial Performance

In 2021, Repligen's revenue was $670.53 million, an increase of 83.08% compared to the previous year's $366.26 million. Earnings were $128.29 million, an increase of 114.08%.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for RGEN stock is "Buy." The 12-month stock price forecast is 244.67, which is an increase of 63.16% from the latest price.

Price Target
$244.67
(63.16% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Will Repligen's (RGEN) COVID Woes Be Offset by Product Demand?

The declining pace of COVID-19 vaccination programs is likely to hurt Repligen's (RGEN) revenue growth rate in 2022. However, the strong core business is likely to offer a respite.

12 hours ago - Zacks Investment Research

Repligen (RGEN) Q1 Earnings and Sales Beat Estimates, Stock Up

Repligen (RGEN) reports encouraging first-quarter results with both sales and earnings beating estimates. RGEN also reduced its financial guidance for 2022

2 weeks ago - Zacks Investment Research

Why Repligen Is Up More Than 10% Today

A stronger-than-expected earnings report calls months of the stock's weakness into question.

2 weeks ago - The Motley Fool

Repligen (RGEN) Beats Q1 Earnings and Revenue Estimates

Repligen (RGEN) delivered earnings and revenue surprises of 27.78% and 12.45%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

Repligen Reports First Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance

—Record revenue of $206.4 million for the quarter, and year-over-year growth of 45% as reported and 48% at constant currency

2 weeks ago - GlobeNewsWire

2 Reasons to Buy Repligen, and 1 Reason to Sell

Management has executed its strategy well, but a potential risk is looming.

1 month ago - The Motley Fool

Repligen to Report First Quarter 2022 Financial Results

Webcast and Conference Call to Be Held Wednesday, April 27, 2022 at 8:30 a.m. EDT Webcast and Conference Call to Be Held Wednesday, April 27, 2022 at 8:30 a.m. EDT

1 month ago - GlobeNewsWire

2 Top Biotech Stocks to Buy for the Long Haul

Repligen and Exact Sciences have a proven track record with significant opportunities for continued growth.

Other symbols:EXAS
1 month ago - The Motley Fool

Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum

WALTHAM, Mass., March 18, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtua...

1 month ago - GlobeNewsWire

908 Devices Appoints Tony J. Hunt, President and CEO, Repligen, to its Board of Directors

BOSTON--(BUSINESS WIRE)--908 Devices has appointed Tony J. Hunt, President and CEO of Repligen Corporation to serve on its Board of Directors effective immediately.

Other symbols:MASS
2 months ago - Business Wire

Repligen (RGEN) Q4 Earnings and Revenues Surpass Estimates

Repligen's (RGEN) fourth-quarter earnings and revenues beat estimates. It expects to achieve revenue growth in the range of 19-24% in 2022.

2 months ago - Zacks Investment Research

Repligen (RGEN) Tops Q4 Earnings and Revenue Estimates

Repligen (RGEN) delivered earnings and revenue surprises of 24.62% and 3.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Repligen Reports Fourth Quarter and Full Year 2021 Financial Results

— Record revenue of $186.5 million for the quarter, and year-over-year growth of 72%

2 months ago - GlobeNewsWire

Medical Stocks' Q4 Earnings on Feb 17: RGEN, IRWD & More

Let us take a look at four biotech or drug companies - RGEN, IRWD, EXEL and LGND - due to release their quarterly results on Feb 16.

Other symbols:EXELIRWDLGND
3 months ago - Zacks Investment Research

Repligen Launches AAV Affinity Resins for Gene Therapy Purification

AVIPure® affinity resins address the market need for high performance and caustic stability AVIPure® affinity resins address the market need for high performance and caustic stability

3 months ago - GlobeNewsWire

Repligen Corporation to Present at 11th Annual SVB Leerink Healthcare Conference

WALTHAM, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtual...

3 months ago - GlobeNewsWire

Repligen (RGEN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Repligen to Report Fourth Quarter and Full Year 2021 Financial Results

Webcast and Conference Call to Be Held Thursday, February 17, 2022 at 8:30 a.m. EST Webcast and Conference Call to Be Held Thursday, February 17, 2022 at 8:30 a.m. EST

3 months ago - GlobeNewsWire

4 Top Biotech Stocks to Gain Amid Industry Challenges

New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position VRTX, REGN, DVAX ...

Other symbols:DVAXREGNVRTX
3 months ago - Zacks Investment Research

2 Healthcare Stocks That Could Help Set You Up for Life

These two companies offer under-the-radar ways to invest in the healthcare space.

Other symbols:RMD
3 months ago - The Motley Fool

Down 16.5% in 4 Weeks, Here's Why Repligen (RGEN) Looks Ripe for a Turnaround

Repligen (RGEN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ea...

4 months ago - Zacks Investment Research

Repligen Corporation to Present at 40th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtual...

4 months ago - GlobeNewsWire

3 Biotech Stocks Worth Adding to Your Portfolio Next Year

Here we present three biotech companies, which are likely to perform well in 2022, backed by strong fundamentals.

Other symbols:BGNESRPT
4 months ago - Zacks Investment Research

Repligen (RGEN) Upgraded to Strong Buy: Here's Why

Repligen (RGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

4 months ago - Zacks Investment Research

Is Repligen (RGEN) Stock Outpacing Its Medical Peers This Year?

Here is how Repligen (RGEN) and Roche Holding AG (RHHBY) have performed compared to their sector so far this year.

5 months ago - Zacks Investment Research